Celldex Therapeutics (CLDX) Projected to Post Earnings on Monday

Celldex Therapeutics (NASDAQ:CLDX) is expected to release its earnings data before the market opens on Monday, February 24th. Analysts expect Celldex Therapeutics to post earnings of ($0.73) per share and revenue of $1.31 million for the quarter.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $22.46 on Friday. Celldex Therapeutics has a one year low of $20.91 and a one year high of $53.18. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -8.74 and a beta of 1.60. The stock has a 50 day moving average price of $24.39 and a 200 day moving average price of $29.44.

Analyst Upgrades and Downgrades

CLDX has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Thursday, December 19th. UBS Group initiated coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $60.22.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.